Elicio Therapeutics to be Acquired by Angion Biomedica
Ticker: ELTX · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
Elicio Therapeutics is getting bought by Angion Biomedica, deal expected to close Q2 2024.
AI Summary
Elicio Therapeutics, Inc. announced on April 5, 2024, that it has entered into a definitive agreement to be acquired by Angion Biomedica Corp. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition will combine Elicio's AMPLIFY platform with Angion's pipeline, aiming to create a diversified biopharmaceutical company.
Why It Matters
This acquisition signals consolidation in the biopharmaceutical sector, potentially impacting the development and availability of Elicio's novel immunotherapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the success of the combined entity's pipeline remains uncertain.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Acquiring Company
- April 5, 2024 (date) — Date of Report
- second quarter of 2024 (date) — Expected Closing Period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Elicio Therapeutics, Inc. has entered into a definitive agreement to be acquired by Angion Biomedica Corp.
When is the acquisition expected to close?
The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.
What is the name of the acquiring company?
The acquiring company is Angion Biomedica Corp.
What is Elicio Therapeutics, Inc.'s former company name?
Elicio Therapeutics, Inc.'s former company name was Angion Biomedica Corp. prior to a name change on February 28, 2014.
What is the address of Elicio Therapeutics, Inc.'s principal executive offices?
The address of Elicio Therapeutics, Inc.'s principal executive offices is 451 D Street, 5th Floor, Boston, Massachusetts 02210.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-04-05 16:33:57
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
Filing Documents
- angn-20240405.htm (8-K) — 22KB
- eliciotherapeutics_aacrr.htm (EX-99.1) — 19KB
- eliciotherapeutics_aacrr001.jpg (GRAPHIC) — 277KB
- eliciotherapeutics_aacrr002.jpg (GRAPHIC) — 272KB
- eliciotherapeutics_aacrr003.jpg (GRAPHIC) — 269KB
- eliciotherapeutics_aacrr004.jpg (GRAPHIC) — 284KB
- eliciotherapeutics_aacrr005.jpg (GRAPHIC) — 219KB
- 0001601485-24-000025.txt ( ) — 1994KB
- angn-20240405.xsd (EX-101.SCH) — 2KB
- angn-20240405_lab.xml (EX-101.LAB) — 22KB
- angn-20240405_pre.xml (EX-101.PRE) — 13KB
- angn-20240405_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 5, 2024, Elicio Therapeutics, Inc. (the "Company") issued a press release announcing its presentation of updated clinical T cell and antigen spreading response data from its ongoing Phase 1 (AMPLIFY-201) study of ELI-002 and preclinical data on ELI-007 and ELI-008 at the American Association for Cancer Research Annual Meeting being held April 5-10, 2024 in San Diego, California. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated April 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: April 5, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)